9.5499

5.91% -0.60

After Hours: 9.5499

Surrozen Inc (SRZN)

Overview News Price History Financials Discussions Forecast

Surrozen Inc stock is currently priced at $9.5499, with a 24-hour trading volume of 7,727. It has seen a -5.91% decreased in the last 24 hours and a +2.03% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $9.92 pivot point. If it approaches the $9.53 support level, significant changes may occur.

Previous Close:

$10.15

Open:

$9.93

24h Volume:

7,727

Market Cap:

$30.55M

Revenue:

Net Income/Loss:

$-34.90M

P/E Ratio:

-7.9583

EPS:

-1.2

Net Cash Flow:

$-33.80M

1W Performance:

-8.17%

1M Performance:

+2.03%

6M Performance:

+1,976%

1Y Performance:

+1,636%

1D Range:

$9.3001

$9.94

52W Range:

$0.30

$16.19

Surrozen Inc Stock (SRZN) Company Profile

Name

Surrozen Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650 489 9000

Address

171 Oyster Point Boulevard, Suite 400, South San Francisco

Employee

Twitter

Next Earnings Date

2024-05-07

Latest SEC Filings

SRZN's Discussions on Twitter

Surrozen Inc Stock (SRZN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-11-21	Initiated	BofA Securities	Buy
Sep-15-21	Initiated	Guggenheim	Buy
Sep-07-21	Initiated	Stifel	Buy

Surrozen Inc Stock (SRZN) Latest News

When the Price of (SRZN) Talks, People Listen - Stock Traders Daily

Stock Traders Daily

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial ... - GlobeNewswire

GlobeNewswire

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

GlobeNewswire Inc.

Surrozen presents data demonstrating potentialfor Wnt mimetic technologies - TipRanks.com - TipRanks

TipRanks

Surrozen Provides First Quarter 2024 Financial Results and Business Update - Yahoo Finance

Yahoo Finance

Surrozen Provides First Quarter 2024 Financial Results and Business Update - Yahoo Finance

Yahoo Finance

Surrozen Inc Stock (SRZN) Financials Data

Surrozen Inc (SRZN) Net Income 2024

SRZN net income (TTM) was -$34.90 million for the quarter ending September 30, 2023, a +30.45% increase year-over-year.

Surrozen Inc (SRZN) Cash Flow 2024

SRZN recorded a free cash flow (TTM) of -$33.80 million for the quarter ending September 30, 2023, a +40.05% increase year-over-year.

Surrozen Inc (SRZN) Earnings per Share 2024

SRZN earnings per share (TTM) was -$17.40 for the quarter ending September 30, 2023, a +14.71% growth year-over-year.

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.